CurrentAvMedPolicy N/A

IV tocilizumab prior authorization (medical)

Prior authorization and step-edit requirements for intravenous tocilizumab products (Actemra, Tyenne, Tofidence) for AvMed members, including clinical criteria, prescriber and documentation requirements. Applies to providers requesting medical (infused) tocilizumab for covered members.

Policy Summary

PayerAvMed

PolicyIV tocilizumab prior authorization (medical)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a completed prior authorization form with prescriber signature, diagnosis, supporting documentation (labs, chart notes), and documentation of prior DMARD trial/failures.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1DMARD trial required

18+Min age — RA

2Min age — JIA

CRP>15sJIA CRP threshold

ESR>45sJIA ESR threshold

Coverage Criteria for IV Tocilizumab

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Rheumatoid Arthritis (RA) Initial Authorization

Covered when ALL of the following are met

RA initial criteria: Prescriber is a Rheumatologist; Member is 18 years of age or older; Member tried and failed at least one previous DMARD therapy for three (3) months (refer to Part A list); Member tried and failed both Cimzia and Renflexis (these require separate prior authorization); For Tofidence requests: member must have tried and failed BOTH preferred agents Actemra and Tyenne and meet all prior authorization criteria.

All criteria must be documented; Cimzia and Renflexis require prior authorization separately.

Juvenile Idiopathic Arthritis (JIA) Initial Authorization

Covered when ALL of the following are met

JIA initial criteria: Prescriber is a Rheumatologist; Member is 2 years of age or older; Trial and failure of at least one (1) DMARD therapy for three (3) months (refer to Part A list); For Tofidence requests: member must have tried and failed BOTH preferred agents Actemra and Tyenne and meet all prior authorization criteria.

All criteria must be documented.

Systemic Juvenile Idiopathic Arthritis (sJIA) Initial Authorization

Covered when ALL of the following are met

sJIA initial criteria: Prescriber is a Rheumatologist; Member aged 2 to 17 years; Persistent sJIA activity for a minimum of six months; Date of diagnosis provided; Trial and failure of NSAIDs and high‑dose corticosteroids for >3 months (verified by pharmacy paid claims); Member meets ONE of: ≥5 active joints with fever ≥2 weeks OR ≥2 active joints with fever ≥5 days while taking prednisone ≥0.5 mg/kg/day or 30 mg/day; CRP > 15 mg/L; ESR > 45 mm/hr; Fever > 38°C for at least two weeks; For Tofidence requests: member must have tried and failed BOTH preferred agents Actemra and Tyenne and meet all prior authorization criteria.CRP > 15 mg/L; ESR > 45 mm/hr

Date of diagnosis must be provided; NSAID and steroid treatment duration must be verifiable.

Use of medication samples to initiate therapy is not acceptable to satisfy the prior authorization or step-edit requirements for IV tocilizumab. Samples provided by a prescriber, manufacturer, or other source do not meet the documentation or trial-of-therapy evidence required for approval and should not be relied upon when submitting a PA request.

Authorization requests must include complete, correct, and legible information. If required fields are missing, information is illegible, or supporting documentation (such as lab results, diagnostics, chart notes, or prior therapy verification) is not provided, the request may be delayed or denied. Ensure the prescriber’s signature and all requested member and prescriber details are included to avoid processing delays.

Prior Authorization, Documentation, and Step Requirements

Prior Authorization

Prior authorization required for IV tocilizumab products

Prior authorization is required for all IV tocilizumab products listed on the form: Actemra (J3262), Tyenne (Q5135), and Tofidence (Q5133). Tofidence is designated non-preferred and requires prior failure of both preferred agents plus meeting all PA criteria.

Actemra IV (tocilizumab) — J3262
Tyenne IV (tocilizumab-aazg) — Q5135
Tofidence IV (tocilizumab-bavi) — Q5133 (non-preferred; requires failure of both preferred agents and all PA criteria)

Step Therapy

DMARD trial and non-preferred agent step requirements

Member must have trialed and failed at least one DMARD for three months (see Part A list). For RA and JIA indications prior DMARD failure is required. For Tofidence requests the member must have tried and failed BOTH preferred agents (Actemra and Tyenne) and meet all PA criteria.

DMARD trial examples (Part A): methotrexate, sulfasalazine, azathioprine, leflunomide, auranofin, hydroxychloroquine, or other.
For RA: member must also have tried and failed Cimzia and Renflexis (separate PAs may be required).
For Tofidence: failure of BOTH Actemra and Tyenne is required in addition to meeting all PA criteria.

Documentation Required

Required documentation and form completion

The prescriber must sign the PA request (preprinted stamps not valid) and supply required fields on the form including drug name/dose, dosing schedule, length of therapy, diagnosis and ICD code if applicable, member weight and date, and supporting documentation such as lab results, diagnostics, and chart notes.

Prescribing physician signature and printed name required (preprinted stamps not valid).
Provide drug name/form/strength, dosing schedule, length of therapy, diagnosis and ICD code, weight and date weight obtained, and supporting documentation.

Denial Risk

Incomplete or illegible request

Authorization may be delayed or the request denied if the information provided is incomplete, incorrect, or illegible; all documentation (including lab results, diagnostics, and chart notes) must be provided to support each checked clinical criterion.

Incomplete, incorrect, or illegible information on the form can delay authorization.
Missing supporting documentation for checked clinical criteria may result in denial.

Definitions and Criteria Clarifications

DMARD trial

Required DMARD trial durationTrial and failure of at least one DMARD therapy for three (3) months

Example agents listedmethotrexate, sulfasalazine, azathioprine, leflunomide, auranofin, hydroxychloroquine

DocumentationRefer to PART A for list — check each agent tried on the form

sJIA activity requirements

Minimum duration of persistent sJIA activityPersistent activity for a minimum of six (6) months

Prior therapy requirementsTrial and failure of NSAIDs and high‑dose corticosteroids for >3 months (verified by pharmacy paid claims)

Joint/fever activity criteria (one required)Either ≥5 active joints with fever ≥2 weeks OR ≥2 active joints with fever ≥5 days while on prednisone ≥0.5 mg/kg/day or 30 mg/day

Inflammatory marker thresholdsCRP > 15 mg/L and ESR > 45 mm/hr

OpenPayer

IV tocilizumab prior authorization (medical)

Coverage Criteria for IV Tocilizumab

Codes and Laboratory Thresholds

Prior Authorization, Documentation, and Step Requirements

Definitions and Criteria Clarifications

Clinical Background

J3262	Actemra IV (tocilizumab)
Q5135	Tyenne IV (tocilizumab-aazg)
Q5133	Tofidence IV (tocilizumab-bavi)